Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J forms 'innovation centres' in global biotech hubs to access emerging tech

This article was originally published in Scrip

Executive Summary

Johnson & Johnson's new regional "innovation centres" will expand on the company's success with the US Janssen Labs project that opened earlier this year in San Diego to assist life science startups and connect the pharmaceutical company to promising new therapeutics, medical devices and consumer healthcare products (scripintelligence.com, 20 January 2012).

You may also be interested in...



Finance Watch: Four Biotech VC Funds Raise $1.7bn Combined

Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline. 

'Biomedical Innovation Can Come From Anywhere,' Says JNJ Innovation Head

Richard Mason, head of Johnson & Johnson Innovation, London (EMEA), talks to Scrip senior writer, Lucie Ellis, about why R&D innovation hubs are still necessary to boost new scientific developments in the healthcare sector.

Green Shoots: Pharma Investments In Early Innovation Support Biotech Growth

Big pharma investments in early innovation are paying off in ways that still are hard to measure in any concrete way, but green shoots are sprouting through the pavement as startups supported by multimillion-dollar initiatives evolve from concept to reality.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC018807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel